Luodan Suo

Luodan Suo

Auto-generated profile, based on publicly available information

Luodan Suo

Beijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, 16 Hepingli Middle St, Dongcheng District, Beijing, 100013, China, 86 01064407095

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2026 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
DZDan Zhao
Dan Zhao
YMYing Ma
Ying Ma
JLJuan Li
Juan Li
XLXiaomei Li
Xiaomei Li
ZCZhiqiang Cao
Zhiqiang Cao
LSLuodan Suo
Luodan Suo
Background: A large wave of COVID-19 caused by SARS-CoV-2 Omicron subvariants began in Beijing in early December 2022. Objective: This study aimed to evaluate the COVID-19 vaccine effectiveness (VE) in mitigating the risk of COVID-19–related hospitalization during the epidemic. Methods: We conducted a retrospective cohort study linking regional health care data and vaccination registry routinely collected in Beijing. All electronic medical records on COVID-19–related hospital discharges of older inpatients aged ≥80 years during November 2022 and February 2023 were included. Poisson regressions were used to estimate incidence risk ratio of COVID-19–related hospitalization, severe or critical cases, and in-hospital death compared with unvaccinated groups, adjusting for gender and age. VE was calculated as 1 minus incidence risk ratio×100%. Results: A total of 53,789 individuals aged ≥80 years were included, 28,423 (52.84%) were male, 45,270 (84.16%) were aged 80‐89 years, and 8519 (15.84%) were aged ≥90 years. Overall, 30,531 (56.76%) were in the vaccine group, with 4524 (8.41%) of the total participants receiving partial vaccination, 20.91% completing the primary series, and 14,761 (27.44%) receiving one booster. Additionally, 23,258 (43.24%) were in the unvaccinated group. Of the 53,789 hospitalized individuals, 17,916 (33.31%) had a COVID-19 diagnosis, 3535 (6.57%) had COVID-19–related hospitalization, 961 (1.79%) were COVID-19 severe or critical cases, and 4130 (7.68%) had in-hospital death. The analysis revealed that the VE of booster vaccination in preventing COVID-19–related hospital, severe or critical COVID-19, and in-hospital death was 63.5% (95% CI 59.8%‐66.9%), 66.9% (95% CI 60.1%‐72.6%) and 79.4% (95% CI 77%‐81.5%), the VE of primary series 56% (95% CI 51.4%‐60.2%), 66.8% (95% CI 59%‐73%) and 66.4% (95% CI 63%‐69.5%). Conclusions: The first booster vaccination was associated with significantly reduced the risk of COVID-19–related severe outcomes in older inpatients aged ≥80 years during the Omicron-dominant period. Considering the potential selection bias and unmeasured confounders, these estimates may reflect both the VE and the better baseline health status of the vaccinated older individuals.